SCHEMBL2980221

SCHEMBL2980221

NS(=O)(=O)c1cc(S(=O)(=O)Cl)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.50
CA2 P00918 11/20 0.50
CA9 Q16790 7/20 0.50
CA12 O43570 6/20 0.50
CA4 P22748 6/20 0.50
CA6 P23280 6/20 0.50
CA5A P35218 6/20 0.50
CA7 P43166 6/20 0.50
CA14 Q9ULX7 6/20 0.50
CA5B Q9Y2D0 6/20 0.50
CA13 Q8N1Q1 4/20 0.50
POLB P06746 2/20 0.50
APEX1 P27695 2/20 0.50
LMNA P02545 1/20 0.50
CYP2C9 P11712 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA3 P07451 4/20 0.47
VCAM1 P19320 1/20 0.44
PTGES2 Q9H7Z7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clofenamide SCHEMBL310408 0.88 CA1 (0.59) CA1CA2CA9CA12CA4
Clofenamide SCHEMBL30748198 0.88 CA1 (0.59) CA1CA2CA9CA12CA4
Clofenamide SCHEMBL28383730 0.86 CA1 (0.57) CA1CA2CA9CA12CA4
Clofenamide SCHEMBL27524784 0.86 CA1 (0.57) CA1CA2CA9CA12CA4
SCHEMBL7124035 0.85 POLB (0.47) CA1CA2CA9CA12CA4
SCHEMBL17478768 0.84 CA2 (0.55) CA1CA2CA9CA12CA4
SCHEMBL11009995 0.82 LMNA (0.51) CA1CA2CA9CA12CA4
Clofenamide SCHEMBL28282642 0.79 CA1 (0.50) CA1CA2CA9CA12CA4
SCHEMBL11010701 0.79 CA1 (0.46) CA1CA2CA9CA12CA4
SCHEMBL29469880 0.78 VCAM1 (0.55) CA1CA2CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398341-B2 Apparatus and compositions for improving scent delivery THE PROCTER & GAMBLE COMPANY (US) 2025-08-26 US claimed
US-12247180-B2 Apparatus and compositions for improving scent delivery THE PROCTER & GAMBLE COMPANY (US) 2025-03-11 US claimed
EP-4686751-A1 PROCESS FOR THE PREPARATION OF A DETERGENT CONCENTRATE Henkel AG & Co. KGaA (DE) 2026-02-04 EP disclosed
US-12398341-B2 Apparatus and compositions for improving scent delivery THE PROCTER & GAMBLE COMPANY (US) 2025-08-26 US disclosed
WO-2025131407-A1 HAND DISHWASHING DETERGENT CONCENTRATE HENKEL AG & CO. KGAA (DE) 2025-06-26 WO disclosed
US-20250177596-A1 POLYESTER SOLID ARTICLE COMPRISING HYDROPHOBIC MATERIAL THE PROCTER & GAMBLE COMPANY 2025-06-05 US disclosed
US-20250177597-A1 POLYESTER-POLYETHER SOLID ARTICLE COMPRISING HYDROPHOBIC MATERIAL THE PROCTER & GAMBLE COMPANY 2025-06-05 US disclosed
EP-4006130-B1 ISOMER MIXTURES OF UNSATURATED MACROCYCLIC MUSK COMPOUNDS SYMRISE AG (DE) 2025-04-09 EP disclosed
EP-4531800-A1 TWO-STAGE DYEING METHOD FOR INCREASING THE INTENSITY OF COLORATIONS WITH NATURAL DYES Henkel AG & Co. KGaA (DE) 2025-04-09 EP disclosed
US-12247180-B2 Apparatus and compositions for improving scent delivery THE PROCTER & GAMBLE COMPANY (US) 2025-03-11 US disclosed
CN-119584860-A Comprising biodegradable microcapsule composition 奇华顿股份有限公司 2025-03-07 CN disclosed
US-7781613-B2 Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed
EP-1841731-A1 SUBSTITUTED AMINOMETHYLENE SULPHONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Sanofi-Aventis (FR) 2007-10-10 EP disclosed
WO-2006074957-A9 SUBSTITUTED AMINOMETHYLENE SULPHONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-07-12 WO disclosed
WO-2006074957-A1 SUBSTITUTED AMINOMETHYLENE SULPHONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS (DE) 2006-07-20 WO disclosed
EP-0088350-B1 CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1985-02-20 EP disclosed
US-4431645-A CARDIOVASCULAR DISORDERS; DIURETICS SCHERING CORPORATION (US) 1984-02-14 US disclosed
US-4431644-A CARDIOVASCULAR DISORDERS; DIURETICS SCHERING CORPORATION (US) 1984-02-14 US disclosed
EP-0088350-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1983-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS LIPE, STS, ARSA CA1 3065/4885CA2 2004/4885CA9 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.